ERKKI I RUOSLAHTI

Summary

Affiliation: The Burnham Institute
Country: USA

Publications

  1. ncbi request reprint Drug targeting to specific vascular sites
    Erkki Ruoslahti
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Drug Discov Today 7:1138-43. 2002
  2. ncbi request reprint Vascular homing peptides with cell-penetrating properties
    E Ruoslahti
    The Burnham Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Curr Pharm Des 11:3655-60. 2005
  3. pmc Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels
    Sven Christian
    Cancer Research Center, The Burnham Institute, La Jolla, CA 92037 3198, USA
    J Cell Biol 163:871-8. 2003
  4. ncbi request reprint The RGD story: a personal account
    Erkki Ruoslahti
    The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Matrix Biol 22:459-65. 2003
  5. ncbi request reprint Specialization of tumour vasculature
    Erkki Ruoslahti
    Cancer Research Center, Burnham Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA
    Nat Rev Cancer 2:83-90. 2002
  6. ncbi request reprint Antiangiogenics meet nanotechnology
    Erkki Ruoslahti
    The Burnham Institute, La Jolla, California 92037, USA
    Cancer Cell 2:97-8. 2002
  7. ncbi request reprint Vascular zip codes in angiogenesis and metastasis
    E Ruoslahti
    The Burnham Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Biochem Soc Trans 32:397-402. 2004
  8. pmc Targeting of drugs and nanoparticles to tumors
    Erkki Ruoslahti
    Vascular Mapping Center, Sanford Burnham Medical Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
    J Cell Biol 188:759-68. 2010
  9. ncbi request reprint Targeting tumor vasculature with homing peptides from phage display
    E Ruoslahti
    Cancer Research Center, The Burnham Institute, La Jolla, California 92037, USA
    Semin Cancer Biol 10:435-42. 2000
  10. ncbi request reprint Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
    R Pasqualini
    The Burnham Institute, La Jolla, California 92037, USA
    Cancer Res 60:722-7. 2000

Research Grants

  1. Regulation of Apoptosis by Integrins
    Erkki Ruoslahti; Fiscal Year: 2007
  2. Regulation of Apoptosis by Integrins
    Erkki Ruoslahti; Fiscal Year: 2006
  3. Regulation of Apoptosis by Integrins
    Erkki Ruoslahti; Fiscal Year: 2005
  4. Regulation of Apoptosis by Integrins
    Erkki Ruoslahti; Fiscal Year: 2004
  5. INTEGRIN REGULATION BY R-RAS
    Erkki Ruoslahti; Fiscal Year: 2002
  6. TISSUE TARGETING WITH PHAGE LIBRARIES
    Erkki Ruoslahti; Fiscal Year: 2001
  7. INTEGRIN REGULATION BY R-RAS
    Erkki Ruoslahti; Fiscal Year: 2001
  8. INTEGRIN REGULATION BY R-RAS
    Erkki Ruoslahti; Fiscal Year: 2000
  9. TISSUE TARGETING WITH PHAGE LIBRARIES
    Erkki Ruoslahti; Fiscal Year: 2000
  10. Molecular Specialization of Tumor Lymphatics
    Erkki Ruoslahti; Fiscal Year: 2007

Collaborators

Detail Information

Publications53

  1. ncbi request reprint Drug targeting to specific vascular sites
    Erkki Ruoslahti
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Drug Discov Today 7:1138-43. 2002
    ..Targeting a therapy to the diseased tissue enhances the efficacy of the treatment while reducing the side effects in mouse experiments. Results from drug delivery to tumor vessels have been particularly encouraging...
  2. ncbi request reprint Vascular homing peptides with cell-penetrating properties
    E Ruoslahti
    The Burnham Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Curr Pharm Des 11:3655-60. 2005
    ..The cell penetrating peptides may be particularly useful in drug delivery because they can take their payload inside the target cells and even into a specific subcellular organelle such as the nucleus...
  3. pmc Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels
    Sven Christian
    Cancer Research Center, The Burnham Institute, La Jolla, CA 92037 3198, USA
    J Cell Biol 163:871-8. 2003
    ..These results show that cell surface nucleolin is a specific marker of angiogenic endothelial cells within the vasculature. It may be a useful target molecule for diagnostic tests and drug delivery applications...
  4. ncbi request reprint The RGD story: a personal account
    Erkki Ruoslahti
    The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Matrix Biol 22:459-65. 2003
  5. ncbi request reprint Specialization of tumour vasculature
    Erkki Ruoslahti
    Cancer Research Center, Burnham Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA
    Nat Rev Cancer 2:83-90. 2002
    ..Some tumours also contain lymphatic vessels, as well as channels that consist of cancer cells and their extracellular matrix. These special features of tumour vessels are good targets for cancer therapies...
  6. ncbi request reprint Antiangiogenics meet nanotechnology
    Erkki Ruoslahti
    The Burnham Institute, La Jolla, California 92037, USA
    Cancer Cell 2:97-8. 2002
    ..A mutant Raf-1 gene loaded onto nanoparticles, delivered to tumor vasculature with an integrin binding compound, provides effective antiangiogenic gene therapy in mice...
  7. ncbi request reprint Vascular zip codes in angiogenesis and metastasis
    E Ruoslahti
    The Burnham Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Biochem Soc Trans 32:397-402. 2004
    ..These phage-screening studies have revealed a previously unsuspected degree of vascular specialization and provide potentially useful guidance devices for targeted therapies...
  8. pmc Targeting of drugs and nanoparticles to tumors
    Erkki Ruoslahti
    Vascular Mapping Center, Sanford Burnham Medical Research Institute, University of California, Santa Barbara, Santa Barbara, CA 93106, USA
    J Cell Biol 188:759-68. 2010
    ..We review the recent advances in this delivery approach with a focus on the use of molecular markers of tumor vasculature as the primary target and nanoparticles as the delivery vehicle...
  9. ncbi request reprint Targeting tumor vasculature with homing peptides from phage display
    E Ruoslahti
    Cancer Research Center, The Burnham Institute, La Jolla, California 92037, USA
    Semin Cancer Biol 10:435-42. 2000
    ..Such a targeting strategy can therefore potentially improve the efficacy of drugs and reduce their side effects...
  10. ncbi request reprint Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis
    R Pasqualini
    The Burnham Institute, La Jolla, California 92037, USA
    Cancer Res 60:722-7. 2000
    ..Thus, APN is involved in angiogenesis and can serve as a target for delivering drugs into tumors and for inhibiting angiogenesis...
  11. pmc Nanocrystal targeting in vivo
    Maria E Akerman
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 99:12617-21. 2002
    ..These results encourage the construction of more complex nanostructures with capabilities such as disease sensing and drug delivery...
  12. pmc Tissue-penetrating delivery of compounds and nanoparticles into tumors
    Kazuki N Sugahara
    Vascular Mapping Center, Burnham Institute for Medical Research at UCSB, Biology II Building, University of California, Santa Barbara, Santa Barbara, CA 93106 9610, USA
    Cancer Cell 16:510-20. 2009
    ..Conjugation to iRGD significantly improved the sensitivity of tumor-imaging agents and enhanced the activity of an antitumor drug...
  13. pmc Nanoparticle-induced vascular blockade in human prostate cancer
    Lilach Agemy
    Vascular Mapping Laboratory, Center for Nanomedicine, Sanford Burnham Medical Research Institute at the University of California at Santa Barbara UCSB, Santa Barbara, CA, USA
    Blood 116:2847-56. 2010
    ..Treatment of mice with prostate cancer with multiple doses of the nanoworms induced tumor necrosis and a highly significant reduction in tumor growth...
  14. ncbi request reprint A tumor-homing peptide with a targeting specificity related to lymphatic vessels
    Pirjo Laakkonen
    Cancer Research Center, The Burnham Institute, La Jolla, California, USA
    Nat Med 8:751-5. 2002
    ..These results suggest that tumor lymphatics carry specific markers and that it may be possible to specifically target therapies into tumor lymphatics...
  15. pmc Molecular changes in the vasculature of injured tissues
    Tero A H Järvinen
    Cancer Research Center, Burnham Institute for Medical Research, La Jolla, CA, USA
    Am J Pathol 171:702-11. 2007
    ..The peptides recognizing these markers may be useful in delivering treatments into regenerating tissues...
  16. pmc Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature
    Markus Essler
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 99:2252-7. 2002
    ..These results indicate that aminopeptidase P is the receptor for the breast-homing peptide. This peptide may be useful in designing drugs for the prevention and treatment of breast cancer...
  17. ncbi request reprint Molecular profiling of heart endothelial cells
    Lianglin Zhang
    Cancer Research Center, The Burnham Institute, La Jolla, CA 92037, USA
    Circulation 112:1601-11. 2005
    ..In this study, we probed the heart vasculature for heart-specific endothelial markers by phage display...
  18. pmc Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds
    Jan Pilch
    Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 103:2800-4. 2006
    ..These peptides may be useful in targeting diagnostic and therapeutic materials into tumors and injured tissues...
  19. ncbi request reprint Lymphatic zip codes in premalignant lesions and tumors
    Lianglin Zhang
    Cancer Research Center and Program in Molecular Pathology, Burnham Institute for Medical Research, La Jolla, California, USA
    Cancer Res 66:5696-706. 2006
    ....
  20. pmc Targeting of albumin-embedded paclitaxel nanoparticles to tumors
    Priya Prakash Karmali
    Vascular Mapping Center, Burnham Institute for Medical Research at UCSB, University of California, Santa Barbara, California 93106 9610, USA
    Nanomedicine 5:73-82. 2009
    ..These results show that nanoparticles can be effectively targeted into extravascular tumor tissue and that targeting can enhance the activity of a therapeutic nanoparticle...
  21. pmc C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
    Tambet Teesalu
    Vascular Mapping Center, The Burnham Institute for Medical Research at University of California, Santa Barbara, CA 93106 9610, USA
    Proc Natl Acad Sci U S A 106:16157-62. 2009
    ..The peptides were able to take payloads up to the nanoparticle size scale deep into extravascular tissue. Our observations have implications in drug delivery and penetration of tissue barriers and tumors...
  22. pmc Biomimetic amplification of nanoparticle homing to tumors
    Dmitri Simberg
    Cancer Research Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 104:932-6. 2007
    ..The self-amplifying homing is a novel function for nanoparticles. The clotting-based amplification greatly enhances tumor imaging, and the addition of a drug carrier function to the particles is envisioned...
  23. pmc Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity
    Ming Yi
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 100:11435-8. 2003
    ....
  24. pmc Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature
    Maria E Akerman
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 102:2040-5. 2005
    ..This functional convergence of several antiangiogenic factors has important implications for antiangiogenic therapies...
  25. ncbi request reprint Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis
    Johanna A Joyce
    Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA
    Cancer Cell 4:393-403. 2003
    ..One peptide is homologous with pro-PDGF-B, which is expressed in endothelial cells, while its receptor is expressed in pericytes...
  26. pmc Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells
    Pirjo Laakkonen
    The Burnham Institute, La Jolla, CA 92037
    Proc Natl Acad Sci U S A 101:9381-6. 2004
    ..As LyP-1 affects the poorly vascularized tumor compartment, it may complement treatments directed at tumor blood vessels...
  27. ncbi request reprint Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma
    Jason A Hoffman
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cancer Cell 4:383-91. 2003
    ..Thus, characteristics of the angiogenic vasculature distinguish premalignant and malignant stages of skin tumorigenesis...
  28. ncbi request reprint Targeted quantum dot conjugates for siRNA delivery
    Austin M Derfus
    Department of Bioengineering, University of California at San Diego, La Jolla, California 92093, USA
    Bioconjug Chem 18:1391-6. 2007
    ..By designing the siRNA sequence against a therapeutic target (e.g., oncogene) instead of EGFP, this technology may be ultimately adapted to simultaneously treat and image metastatic cancer...
  29. pmc Biodegradable luminescent porous silicon nanoparticles for in vivo applications
    Ji Ho Park
    Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093, USA
    Nat Mater 8:331-6. 2009
    ..These results demonstrate a new type of multifunctional nanostructure with a low-toxicity degradation pathway for in vivo applications...
  30. pmc Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting
    Ji Ho Park
    Materials Science and Engineering Program Department of Chemistry and Biochemistry University of California, San Diego 9500 Gilman, La Jolla, CA 92093, USA
    Small 5:694-700. 2009
    ..It is concluded that the blood half-life of a targeting molecule-nanomaterial ensemble is a key consideration when selecting the appropriate ligand and nanoparticle chemistry for tumor targeting...
  31. pmc Contact activation of kallikrein-kinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo
    Dmitri Simberg
    Nano Tumor Center of Excellence for Cancer Nanotechnology, Moores UCSD Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093, USA
    J Control Release 140:301-5. 2009
    ..These data could help in understanding the toxicity of nanomaterials and could be used in designing nanoparticles with controlled enzymatic activity...
  32. ncbi request reprint Metadherin, a cell surface protein in breast tumors that mediates lung metastasis
    Darren M Brown
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037 USA
    Cancer Cell 5:365-74. 2004
    ....
  33. pmc Cooperative nanomaterial system to sensitize, target, and treat tumors
    Ji Ho Park
    Materials Science and Engineering Program, University of California, San Diego, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 107:981-6. 2010
    ..Mice containing xenografted MDA-MB-435 tumors that are treated with the combined NR/LyP-1LP therapeutic system display significant reductions in tumor volume compared with individual nanoparticles or untargeted cooperative system...
  34. pmc Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs
    Kazuki N Sugahara
    Vascular Mapping Laboratory, Center for Nanomedicine, Sanford Burnham Medical Research Institute at University of California at Santa Barbara, Biology II Building, University of California, Santa Barbara, CA 93106 9610, USA
    Science 328:1031-5. 2010
    ..Thus, coadministration of iRGD may be a valuable way to enhance the efficacy of anticancer drugs while reducing their side effects, a primary goal of cancer therapy research...
  35. pmc Protein kinase D is a positive regulator of Bit1 apoptotic function
    Hector Biliran
    Burnham Institute for Medical Research at the University of California Santa Barbara, University of California, Santa Barbara, California 93106 9610, USA
    J Biol Chem 283:28029-37. 2008
    ..These studies identify the PKD serine/threonine kinase as one of the signaling molecules through which integrin-mediated cell attachment controls Bit1 activity and anoikis...
  36. pmc Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance
    Dmitri Simberg
    Moores UCSD Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093, USA
    Biomaterials 30:3926-33. 2009
    ..These data provide guidance to rational design of bioinert, long-circulating nanoparticles...
  37. pmc Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation
    Valentina Fogal
    Cancer Research Center, Burnham Institute for Medical Research, 10901 N Torrey Pines Rd, La Jolla, California 92037, USA
    Mol Cell Biol 30:1303-18. 2010
    ....
  38. pmc Targeting the prostate for destruction through a vascular address
    Wadih Arap
    Cancer Research Center, The Burnham Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 99:1527-31. 2002
    ..These results suggest that it may be possible to develop an alternative to surgical prostate resection and that such a treatment may also reduce future cancer risk...
  39. ncbi request reprint Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature
    Valentina Fogal
    Cancer Research Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Angiogenesis 12:91-100. 2009
    ..These data reveal a novel mode of action for anti-angiogenic therapy and identify cell surface nucleolin as a novel target for combinatorial chemotherapy...
  40. pmc Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery
    Ji Ho Park
    Materials Science and Engineering Program, Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman, La Jolla, CA 92093, USA
    Angew Chem Int Ed Engl 47:7284-8. 2008
  41. ncbi request reprint Identification of endothelial genes up-regulated in vivo
    Jih tung Pai
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Gene 347:21-33. 2005
    ..In summary, the genes we have identified represent potentially new pan-endothelial and tissue-specific endothelial markers...
  42. pmc A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo
    Kimmo Porkka
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 99:7444-9. 2002
    ..Thus, F3 can carry a payload (phage, fluorescein) to a tumor and into the cell nuclei in the tumor. This peptide may be suitable for targeting cytotoxic drugs and gene therapy vectors into tumors...
  43. ncbi request reprint R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis
    Masanobu Komatsu
    Burnham Institute for Medical Research, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, California 92037, USA
    Nat Med 11:1346-50. 2005
    ..These results establish an unexpected role for R-Ras in blood vessel homeostasis and suggest that R-Ras signaling may offer a target for therapeutic intervention in vascular diseases...
  44. ncbi request reprint Drug identification through in vivo screening of chemical libraries
    Darren M Brown
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Chembiochem 5:871-5. 2004
  45. ncbi request reprint A mitochondrial protein, Bit1, mediates apoptosis regulated by integrins and Groucho/TLE corepressors
    Yiwen Jan
    Cancer Research Center, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 116:751-62. 2004
    ..Thus, we have elucidated an integrin-controlled pathway that is, at least in part, responsible for the cell survival effects of cell-ECM interactions...
  46. ncbi request reprint Anastellin, an FN3 fragment with fibronectin polymerization activity, resembles amyloid fibril precursors
    Klára Briknarová
    The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037 1062, USA
    J Mol Biol 332:205-15. 2003
    ..We suggest that this analogy is not random and may reflect similarities between fibronectin and amyloid fibril formation...
  47. pmc Dynamic imaging of arginine-rich heart-targeted vehicles in a mouse model
    Hua Zhang
    Department of Biomedical Engineering, University of California, Davis, CA 95616, USA
    Biomaterials 29:1976-88. 2008
    ..The rapid and efficient targeting of these particles can be exploited in drug and gene delivery systems and with dynamic positron emission tomography provides a model system to optimize targeting of engineered particles...
  48. ncbi request reprint Crystal structure of a human peptidyl-tRNA hydrolase reveals a new fold and suggests basis for a bifunctional activity
    Jose M de Pereda
    Program on Cell Adhesion and Signal Transduction, Cancer Center of the Burnham Institute, La Jolla, California 92037, USA
    J Biol Chem 279:8111-5. 2004
    ..This active site architecture is unrelated to that of E. coli Pth. In addition, intermolecular contacts in the crystal asymmetric unit cell suggest a likely surface for protein-protein interactions related to the Pth2-mediated apoptosis...
  49. ncbi request reprint Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype
    Ghiabe H Guibinga
    Department of Pediatrics, Center for Molecular Genetics, University of California at San Diego School of Medicine, La Jolla, CA 92093 0634, USA
    Mol Ther 9:76-84. 2004
    ....
  50. pmc Trophoblast cell activation by trophinin ligation is implicated in human embryo implantation
    Kazuhiro Sugihara
    Cancer Research Center and Inflammation and Infectious Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037
    Proc Natl Acad Sci U S A 104:3799-804. 2007
    ..These results suggest that trophinin-mediated cell adhesion functions as a molecular switch for trophectoderm activation in human embryo implantation...
  51. doi request reprint Synthetic surfaces for human embryonic stem cell culture
    Poornima Kolhar
    Biomolecular Science and Engineering, University of California, Santa Barbara, CA 93106, USA
    J Biotechnol 146:143-6. 2010
    ..We have developed a novel peptide-based surface that uses a high-affinity cyclic RGD peptide for culture of hESCs under chemically defined conditions...
  52. ncbi request reprint Activated SRC oncogene phosphorylates R-ras and suppresses integrin activity
    June X Zou
    Cancer Research Center, The Burnham Institute, La Jolla, California 92037, USA
    J Biol Chem 277:1824-7. 2002
    ..Regulation of cell adhesion by Src through R-Ras may be at least partially responsible for the reduced adhesion and the resulting increased invasiveness of Src-transformed cells...
  53. pmc Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma
    Valentina Fogal
    Cancer Research Center, Burnham Institute for Medical Research, La Jolla, California, USA
    Cancer Res 68:7210-8. 2008
    ..Its unique localization in tumors and its relative tumor specificity may make p32 a useful target in tumor diagnosis and therapy...

Research Grants25

  1. Regulation of Apoptosis by Integrins
    Erkki Ruoslahti; Fiscal Year: 2007
    ..Cells that become malignant may bypass this pathway in becoming anchorage independent and metastatic. ..
  2. Regulation of Apoptosis by Integrins
    Erkki Ruoslahti; Fiscal Year: 2006
    ..Cells that become malignant may bypass this pathway in becoming anchorage independent and metastatic. ..
  3. Regulation of Apoptosis by Integrins
    Erkki Ruoslahti; Fiscal Year: 2005
    ..Cells that become malignant may bypass this pathway in becoming anchorage independent and metastatic. ..
  4. Regulation of Apoptosis by Integrins
    Erkki Ruoslahti; Fiscal Year: 2004
    ..Cells that become malignant may bypass this pathway in becoming anchorage independent and metastatic. ..
  5. INTEGRIN REGULATION BY R-RAS
    Erkki Ruoslahti; Fiscal Year: 2002
    ..As the R-ras interactions we have uncovered are novel for the Ras protein superfamily, new information on this important family of cellular regulators and oncoproteins will ensue. ..
  6. TISSUE TARGETING WITH PHAGE LIBRARIES
    Erkki Ruoslahti; Fiscal Year: 2001
    ..Major advances in tumor therapies could be realized with this technology. Valuable information on the distinguishing characteristics of different vascular beds, including those undergoing angiogenesis, is also likely to ensue. ..
  7. INTEGRIN REGULATION BY R-RAS
    Erkki Ruoslahti; Fiscal Year: 2001
    ..As the R-ras interactions we have uncovered are novel for the Ras protein superfamily, new information on this important family of cellular regulators and oncoproteins will ensue. ..
  8. INTEGRIN REGULATION BY R-RAS
    Erkki Ruoslahti; Fiscal Year: 2000
    ..As the R-ras interactions we have uncovered are novel for the Ras protein superfamily, new information on this important family of cellular regulators and oncoproteins will ensue. ..
  9. TISSUE TARGETING WITH PHAGE LIBRARIES
    Erkki Ruoslahti; Fiscal Year: 2000
    ..Major advances in tumor therapies could be realized with this technology. Valuable information on the distinguishing characteristics of different vascular beds, including those undergoing angiogenesis, is also likely to ensue. ..
  10. Molecular Specialization of Tumor Lymphatics
    Erkki Ruoslahti; Fiscal Year: 2007
    ..Promising compounds emerging from these experiments will be tested in pre-clinical cancer models for treatment of cancer and prevention of metastasis. ..
  11. Molecular Specialization of Tumor Lymphatics
    Erkki Ruoslahti; Fiscal Year: 2006
    ..Promising compounds emerging from these experiments will be tested in pre-clinical cancer models for treatment of cancer and prevention of metastasis. ..
  12. Molecular Specialization of Tumor Lymphatics
    Erkki Ruoslahti; Fiscal Year: 2005
    ..Promising compounds emerging from these experiments will be tested in pre-clinical cancer models for treatment of cancer and prevention of metastasis. ..
  13. ANGIOGENESIS INHIBITORS: A MECHANISM OF ACTION
    Erkki Ruoslahti; Fiscal Year: 2004
    ..This study may provide important information on the mechanism of action of a class of angiogenesis inhibitors, information that may prove helpful in designing clinical trials for these compounds. ..
  14. ANGIOGENESIS INHIBITORS: A MECHANISM OF ACTION
    Erkki Ruoslahti; Fiscal Year: 2003
    ..This study may provide important information on the mechanism of action of a class of angiogenesis inhibitors, information that may prove helpful in designing clinical trials for these compounds. ..
  15. TISSUE TARGETING WITH PHAGE LIBRARIES
    Erkki Ruoslahti; Fiscal Year: 1999
    ..Major advances in tumor therapies could be realized with this technology. Valuable information on the distinguishing characteristics of different vascular beds, including those undergoing angiogenesis, is also likely to ensue. ..
  16. TUMOR CELLS IN CIRCULATION
    Erkki Ruoslahti; Fiscal Year: 2001
    ..Finally, the ability to eliminate tumor cells from the circulation by sFN administration may provide additional protection against tumor cell transfer in bone marrow transplantation used to treat cancer and against tumor metastasis. ..
  17. TUMOR CELLS IN CIRCULATION
    Erkki Ruoslahti; Fiscal Year: 1999
    ..Finally, the ability to eliminate tumor cells from the circulation by sFN administration may provide additional protection against tumor cell transfer in bone marrow transplantation used to treat cancer and against tumor metastasis. ..
  18. TUMOR CELLS IN CIRCULATION
    Erkki Ruoslahti; Fiscal Year: 2000
    ..Finally, the ability to eliminate tumor cells from the circulation by sFN administration may provide additional protection against tumor cell transfer in bone marrow transplantation used to treat cancer and against tumor metastasis. ..
  19. INTEGRIN REGULATION BY R-RAS
    Erkki Ruoslahti; Fiscal Year: 1999
    ..As the R-ras interactions we have uncovered are novel for the Ras protein superfamily, new information on this important family of cellular regulators and oncoproteins will ensue. ..
  20. ANGIOGENESIS INHIBITORS: A MECHANISM OF ACTION
    Erkki Ruoslahti; Fiscal Year: 2005
    ..This study may provide important information on the mechanism of action of a class of angiogenesis inhibitors, information that may prove helpful in designing clinical trials for these compounds. ..
  21. ANGIOGENESIS INHIBITORS: A MECHANISM OF ACTION
    Erkki Ruoslahti; Fiscal Year: 2006
    ..This study may provide important information on the mechanism of action of a class of angiogenesis inhibitors, information that may prove helpful in designing clinical trials for these compounds. ..